Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy with Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma
Дата публикации: 13-08-2026 07:08:00

Findings from the ENDURANCE study

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma0509-07-2026
2Talquetamab Plus Daratumumab and Pomalidomide and Talquetamab Plus Daratumumab Prolong PFS Among Previously Treated Patients with Relapsed Or Refractory Multiple Myeloma0502-07-2026
3Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC016.811-08-2026
4Intermittent reduced-dose methotrexate enabled continuation of induction therapy despite severe delayed methotrexate elimination in primary central nervous system lymphoma: a case report0516-07-2026
5Adding Pirtobrutinib to Venetoclax-Rituximab Shows Significant Improvement in PFS Among Patients with Previously Treated CLL014.7606-08-2026
6EMA Recommends Extension of Therapeutic Indications for Cetuximab011.314-08-2026
7EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength09.6407-08-2026
8EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan0510-07-2026
9Benefit of Adjuvant Chemotherapy in Patients with ctDNA-positive Resected Stage II Colon Cancer014.7630-07-2026
10STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class04.2314-08-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 11.26. Источник: www.esmo.org.